A novel ryanodine receptor 2 inhibitor, M201-A, enhances natriuresis, renal function and lusi-inotropic actions: Preclinical and phase I study.

Noboru KanekoChristopher M Loughrey Godfrey L SmithRyuko MatsudaTomoko HasunumaPatric B MarkMasashi TodaMakoto ShinozakiNaoyuki OtaniScott KayleyAna Da Silva CostaTamara P MartinSara DobiPriyanka SaxenaKen ShimamotoTetsuya IshikawaRyuichi KambayashiAlexandra RiddellElspeth B ElliottCharlotte S McCarrollToshiya SakaiYamano MitsuhisaSayuri HiranoTakeshi KitaiKengo KusanoYuko InoueMasahiko NakamuraMigaku KikuchiShigeru ToyodaIsao TaguchiToshihiko FujiwaraAtsushi SugiyamaYuji KumagaiKunio Iwata

Published in: British journal of pharmacology (2024)

leak via RyR2, improved cardiac lusi-inotropic effects in rats, and enhanced natriuresis and renal function in humans. These findings suggest that this drug may offer a potential new treatment option for chronic kidney disease and heart failure.

Keyphrases

chronic kidney disease
heart failure
left ventricular
end stage renal disease
atrial fibrillation
cell therapy
emergency department
mesenchymal stem cells
risk assessment
cardiac resynchronization therapy
acute heart failure
binding protein
electronic health record